The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The emergence and spread of multidrug-resistant Plasmodium falciparum in the Greater Mekong Subregion (GMS) threatens global malaria elimination efforts. Mass drug administration (MDA), the presumptive antimalarial treatment of an entire population to clear the subclinical parasite reservoir, is a strategy to accelerate malaria elimination. We report a cluster randomised trial to assess the effectiveness of dihydroartemisinin-piperaquine (DP) MDA in reducing falciparum malaria incidence and prevalence in 16 remote village populations in Myanmar, Vietnam, Cambodia, and the Lao People's Democratic Republic, where artemisinin resistance is prevalent. METHODS AND FINDINGS: After establishing vector control and community-based case management and following intensive community engagement, we used restricted randomisation within village pairs to select 8 villages to receive early DP MDA and 8 villages as controls for 12 months, after which the control villages received deferred DP MDA. The MDA comprised 3 monthly rounds of 3 daily doses of DP and, except in Cambodia, a single low dose of primaquine. We conducted exhaustive cross-sectional surveys of the entire population of each village at quarterly intervals using ultrasensitive quantitative PCR to detect Plasmodium infections. The study was conducted between May 2013 and July 2017. The investigators randomised 16 villages that had a total of 8,445 residents at the start of the study. Of these 8,445 residents, 4,135 (49%) residents living in 8 villages, plus an additional 288 newcomers to the villages, were randomised to receive early MDA; 3,790 out of the 4,423 (86%) participated in at least 1 MDA round, and 2,520 out of the 4,423 (57%) participated in all 3 rounds. The primary outcome, P. falciparum prevalence by month 3 (M3), fell by 92% (from 5.1% [171/3,340] to 0.4% [12/2,828]) in early MDA villages and by 29% (from 7.2% [246/3,405] to 5.1% [155/3,057]) in control villages. Over the following 9 months, the P. falciparum prevalence increased to 3.3% (96/2,881) in early MDA villages and to 6.1% (128/2,101) in control villages (adjusted incidence rate ratio 0.41 [95% CI 0.20 to 0.84]; p = 0.015). Individual protection was proportional to the number of completed MDA rounds. Of 221 participants with subclinical P. falciparum infections who participated in MDA and could be followed up, 207 (94%) cleared their infections, including 9 of 10 with artemisinin- and piperaquine-resistant infections. The DP MDAs were well tolerated; 6 severe adverse events were detected during the follow-up period, but none was attributable to the intervention. CONCLUSIONS: Added to community-based basic malaria control measures, 3 monthly rounds of DP MDA reduced the incidence and prevalence of falciparum malaria over a 1-year period in areas affected by artemisinin resistance. P. falciparum infections returned during the follow-up period as the remaining infections spread and malaria was reintroduced from surrounding areas. Limitations of this study include a relatively small sample of villages, heterogeneity between villages, and mobility of villagers that may have limited the impact of the intervention. These results suggest that, if used as part of a comprehensive, well-organised, and well-resourced elimination programme, DP MDA can be a useful additional tool to accelerate malaria elimination. TRIAL REGISTRATION: ClinicalTrials.gov NCT01872702.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Artemisinin Resistance in Plasmodium falciparum Malaria
Dondorp, A. M., Nosten, F., Yi, P., Das, D., Phyo, A. P., Tarning, J., Lwin, K. M., Ariey, F., Hanpithakpong, W., Lee, S. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808859 · Cited by 3,424 · cited 2×
“falciparum was first confirmed in Pailin in western Cambodia more than 10 years ago [27,28].”
BackgroundSelf-citationSpread of Artemisinin Resistance in Plasmodium falciparum Malaria
Ashley, E. A., Dhorda, M., Fairhurst, R. M., Amaratunga, C., Lim, P., Suon, S., Sreng, S., Anderson, J. M., Mao, S., Sam, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314981 · Cited by 2,205 · cited 2×
“At the time of the site selection in 2014, there was no evidence of piperaquine resistance in Binh Phuoc, and cure rates with the first-line treatment dihydroartemisinin-pipera-quine (DP) remained satisfactory [3,25].”
BackgroundSelf-citationA meta-analysis of the association between adherence to drug therapy and mortality
Simpson, S. H., Eurich, D. T., Majumdar, S. R., Padwal, R. S., Tsuyuki, R. T., Varney, J., & Johnson, J. A. (2006) · BMJ · doi:10.1136/bmj.38875.675486.55 · Cited by 1,353 · cited 1×
“Some of the observed higher impact in people who adhered to the complete 3 rounds of MDA compared to people who took part in none or fewer than 3 rounds could be due to the people adhering to the 3 rounds being healthier than the people who did not adhere [66,67].”
BackgroundAverting a malaria disaster: will insecticide resistance derail malaria control?
Hemingway, J., Ranson, H., Magill, A., Kolaczinski, J., Fornadel, C., Gimnig, J., Coetzee, M., Simard, F., Roch, D. K., Hinzoumbe, C. K., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00417-1 · Cited by 562
The epidemiology of malaria in a Karen population on the western border of Thailand.
Luxemburger, C., Thwai, K. L., White, N. J., Webster, H. K., Kyle, D. E., Maelankirri, L., Chongsuphajaisiddhi, T., & Nosten, F. (1996) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(96)90102-9 · Cited by 233 · cited 1×
“Malaria transmission occurs all year but increases during the rainy season, which lasts from June to October in Myanmar, May to November in Vietnam, and May to October in Lao PDR and Cambodia [17–20].”
BackgroundSelf-citationCarrara, V. I., Lwin, K. M., Phyo, A. P., Ashley, E., Wiladphaingern, J., Sriprawat, K., Rijken, M., Boel, M., McGready, R., Proux, S., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001398 · Cited by 185
Self-citation
Cited by
Molecular Mechanisms of Drug Resistance in Plasmodium falciparum Malaria
Wicht, K. J., Mok, S., & Fidock, D. A. (2020) · Annual Review of Microbiology · doi:10.1146/annurev-micro-020518-115546 · Cited by 322
Metadata
- Authors
- von Seidlein, L., Peto, T. J., Landier, J., Nguyen, T.-N., Tripura, R., Phommasone, K., Pongvongsa, T., Lwin, K. M., Keereecharoen, L., Kajeechiwa, L., Thwin, M. M., Parker, D. M., Wiladphaingern, J., Nosten, S., Proux, S., Corbel, V., Tuong-Vy, N., Phuc-Nhi, T. L., Son, D. H., Huong-Thu, P. N., Tuyen, N. T. K., Tien, N. T., Dong, L. T., Hue, D. V., Quang, H. H., Nguon, C., Davoeung, C., Rekol, H., Adhikari, B., Henriques, G., Phongmany, P., Suangkanarat, P., Jeeyapant, A., Vihokhern, B., van der Pluijm, R. W., Lubell, Y., White, L. J., Aguas, R., Promnarate, C., Sirithiranont, P., Malleret, B., Rénia, L., Onsjö, C., Chan, X. H., Chalk, J., Miotto, O., Patumrat, K., Chotivanich, K., Hanboonkunupakarn, B., Jittmala, P., Kaehler, N., Cheah, P. Y., Pell, C., Dhorda, M., Imwong, M., Snounou, G., Mukaka, M., Peerawaranun, P., Lee, S. J., Simpson, J. A., Pukrittayakamee, S., Singhasivanon, P., Grobusch, M. P., Cobelens, F., Smithuis, F., Newton, P. N., Thwaites, G. E., Day, N. P. J., Mayxay, M., Hien, T. T., Nosten, F. H., Dondorp, A. M., & White, N. J.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2019-02-15
- Volume
- 16
- Issue
- 2
- Pages
- e1002745
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2911417422
- Cited by
- 158
- References
- 6
- FWCI
- 24.96
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.